FibroGen Inc. (NASDAQ:FGEN)’s share price traded down 3% during trading on Monday . The company traded as low as $17.18 and last traded at $17.23, with a volume of 453,569 shares traded. The stock had previously closed at $17.76.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Credit Suisse Group AG reaffirmed a “buy” rating on shares of FibroGen in a research note on Wednesday, May 25th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $33.50.

The stock’s 50 day moving average price is $17.28 and its 200-day moving average price is $19.36. The company’s market cap is $1.08 billion.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts anticipate that FibroGen Inc. will post ($1.02) earnings per share for the current fiscal year.

In other news, CEO Thomas B. Neff sold 13,500 shares of FibroGen stock in a transaction that occurred on Tuesday, April 19th. The shares were sold at an average price of $20.21, for a total transaction of $272,835.00. Following the sale, the chief executive officer now owns 3,579,353 shares in the company, valued at $72,338,724.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $19.98, for a total transaction of $539,460.00. Following the sale, the chief executive officer now owns 3,579,353 shares in the company, valued at approximately $71,515,472.94. The disclosure for this sale can be found here.

Other hedge funds have recently bought and sold shares of the company. Cornerstone Capital Management Holdings LLC. purchased a new stake in FibroGen during the fourth quarter worth about $3,067,000. Morgan Stanley raised its stake in FibroGen by 10.8% in the fourth quarter. Morgan Stanley now owns 108,653 shares of the biopharmaceutical company’s stock worth $3,311,000 after buying an additional 10,580 shares in the last quarter. EAM Investors LLC raised its stake in FibroGen by 44.0% in the fourth quarter. EAM Investors LLC now owns 131,564 shares of the biopharmaceutical company’s stock worth $4,009,000 after buying an additional 40,174 shares in the last quarter. ProShare Advisors LLC purchased a new stake in FibroGen during the fourth quarter worth about $1,715,000. Finally, Columbus Circle Investors purchased a new stake in FibroGen during the fourth quarter worth about $4,332,000.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.